ヨーロッパのリンパ脈管筋腫症（LAM）市場
Market Size in USD Billion
CAGR :
% 
 予測期間 |
2021 –2028 |
 市場規模（基準年） |
USD 33.98 Million |
 Market Size (Forecast Year) |
USD 45.85 Million |
 CAGR |
% |
| 主要市場プレーヤー |
ヨーロッパのリンパ脈管筋腫症 (LAM) 市場、疾患タイプ別 (結節性硬化症複合体 LAM、散発性 LAM など)、タイプ別 (診断、治療)、合併症別 (気胸、乳び胸、腎腫瘍、胸水、腫れおよび体液蓄積、その他)、投与経路別 (経口、非経口、その他)、エンドユーザー別 (病院、専門クリニック、診断センター、在宅医療など)、流通チャネル別 (直接入札、病院薬局、小売薬局、オンライン薬局、その他)、国別 (ドイツ、フランス、イタリア、英国、スペイン、オランダ、ロシア、スイス、トルコ、ベルギー、その他のヨーロッパ諸国) 業界動向および 2028 年までの予測。
市場分析と洞察: ヨーロッパのリンパ脈管筋腫症 (LAM) 市場
ヨーロッパのリンパ脈管筋腫症（LAM）市場は、2021年から2028年の予測期間に市場成長が見込まれています。データブリッジマーケットリサーチは、市場は2021年から2028年の予測期間に4.1％のCAGRで成長し、2020年の3,398万米ドルから2028年には4,585万米ドルに達すると分析しています。糖尿病の発生率の上昇とリンパ脈管筋腫症（LAM）に関する新しい技術進歩の成長は、予測期間における市場の需要を推進する主な原動力となる可能性があります。
リンパ脈管筋腫症 (LAM) は、肺系、腎系、リンパ系に影響を及ぼすまれな嚢胞性慢性肺疾患です。リンパ系は、リンパ液と免疫細胞を体全体に輸送する役割を担う、協調的な血管ネットワークで構成されています。LAM は女性に発生します。20 歳から 40 歳前後の女性が LAM と診断されます。結節性硬化症の女性の約 30% が LAM になりやすい傾向があります。結節性硬化症複合体 (TSC)、TSC 1 遺伝子の変異が原因で発生することがよくあります。孤立性または散発性の LAM は、LAM のみの発生を指します。
リンパ管筋腫症は、TSC 1 と TSC 2 という 2 つの遺伝子の突然変異によって発生します。最初の突然変異は遺伝性で、結節性硬化症の患者に発生します。2 番目の突然変異は結節性硬化症とは関連がなく、散発性 LAM と呼ばれます。散発性 LAM の患者も遺伝子変異を持っていますが、遺伝子変異は遺伝性ではなく、子供に受け継がれることはありません。これらの遺伝子変異が発生する理由は不明です。
慢性嚢胞性肺疾患の有病率の増加、女性の血管筋脂肪腫および結節性硬化症の増加、臨床試験の増加は、リンパ管平滑筋腫症 (LAM ) 市場の成長への道を開きます。さらに、リンパ管平滑筋腫症 (LAM ) の新興経済における成長の可能性と製品 (診断機器およびジェネリック医薬品) の増加は、リンパ管平滑筋腫症 (LAM ) 市場の成長を後押しします。ただし、LAM 治療のコストの上昇、課せられた厳格な規制、およびリンパ管平滑筋腫症 (LAM ) が開発途上国で利用できないことは、市場の成長を妨げる制約です。使用される材料の不一致は、市場の成長を妨げる制約です。
ヨーロッパのリンパ脈管筋腫症 (LAM) 市場レポートでは、市場シェア、新開発、製品パイプライン分析、国内および現地の市場プレーヤーの影響の詳細、新たな収益源、市場規制の変更、製品承認、戦略的決定、製品発売、地理的拡大、市場における技術革新の観点から見た機会の分析が提供されます。分析と市場シナリオを理解するには、アナリスト概要についてお問い合わせください。当社のチームが、希望する目標を達成するための収益影響ソリューションの作成をお手伝いします。
ヨーロッパのリンパ脈管筋腫症（LAM）市場の範囲と市場規模
ヨーロッパのリンパ脈管筋腫症 (LAM) 市場は、疾患の種類、タイプ、合併症、投与経路、エンドユーザー、流通チャネルに基づいてセグメント化されています。セグメント間の成長は、ニッチな成長分野と市場にアプローチするための戦略を分析し、コアアプリケーション領域とターゲット市場の違いを決定するのに役立ちます。
- 疾患の種類に基づいて、欧州のリンパ脈管筋腫症（LAM）市場は、結節性硬化症複合体LAMと散発性LAMに分類されます。2021年には、結節性硬化症複合体LAMセグメントが欧州のリンパ脈管筋腫症（LAM）市場を支配しており、欧州の女性人口における血管筋脂肪腫の増加により、市場を支配すると予測されています。
- タイプに基づいて、欧州のリンパ脈管筋腫症（LAM）市場は、診断と治療に分かれています。診断セグメントはさらに、血液検査（血管内皮増殖因子d（vegf-d））と画像検査、肺機能検査、肺生検検査、その他に細分化されています。画像検査はさらに、胸部X線、胸部CTスキャン、腹部MRIなどに細分化されています。肺生検検査はさらに、経気管支肺生検とビデオ補助胸腔鏡下肺生検に細分化されています。治療セグメントはさらに、薬物療法、酸素療法、肺移植に細分化されています。薬物療法はさらに、mTOR阻害剤と気管支拡張薬に細分化されています。mTOR阻害剤はさらに、シロリムス/ラパマイシン、エベロリムスなどに細分化されています。気管支拡張薬は、さらにアルブテロール、フォルモテロール、サルメテロールなどに細分化されます。肺移植は、さらに片肺移植（SLT）と両肺移植（BLT）に細分化されます。2021年には、症例数の増加とジェネリック、診断、肺移植の利用可能性により、治療セグメントが欧州のリンパ脈管筋腫症（LAM）市場を支配しています。
- 合併症に基づいて、欧州のリンパ脈管筋腫症（LAM）市場は、気胸、乳び胸、腎腫瘍、胸水、腫れと体液の蓄積、その他に分類されます。2021年には、肺疾患を患う女性患者の有病率の増加により、気胸セグメントが欧州のリンパ脈管筋腫症（LAM）市場を支配すると予想され、タイムリーな診断と治療が市場を支配すると予測されています。
- 投与経路に基づいて、ヨーロッパのリンパ脈管筋腫症（LAM）市場は、経口、非経口に分類されます。経口セグメントはさらに、錠剤、カプセル、その他に分類されます。非経口セグメントはさらに、静脈内、皮下、その他に分類されます。2021年には、吸収の容易さから経口セグメントがヨーロッパのリンパ脈管筋腫症（LAM）市場を支配すると予想され、ヨーロッパでの経口薬の入手可能性が市場を支配すると予測されています。
- エンドユーザーに基づいて、欧州のリンパ脈管筋腫症（LAM）市場は、病院、専門クリニック、診断センター、在宅医療などに区分されています。2021年には、リンパ脈管筋腫症の治療ニーズの高まりと、欧州の医療インフラの改善により、病院セグメントが欧州のリンパ脈管筋腫症（LAM）市場を支配すると予想されています。
- 流通チャネルに基づいて、欧州リンパ脈管筋腫症（LAM）市場は、直接入札、病院薬局、小売薬局、オンライン薬局、その他に分類されます。2021年には、シロリムス薬へのアクセスの増加、毎日の処方箋数の急増、診断薬や気管支拡張薬の配布に関する連絡数の増加により、直接入札セグメントが欧州リンパ脈管筋腫症（LAM）市場を支配すると予想されます。
ヨーロッパのリンパ脈管筋腫症（LAM）市場の国別分析
ヨーロッパのリンパ脈管筋腫症 (LAM) 市場が分析され、製品とサービス、サンプルの種類、プロセス、アプリケーション、化合物ライブラリのサイズ、エンドユーザー、流通チャネル別に市場規模の情報が提供されます。
ヨーロッパのリンパ脈管筋腫症 (LAM) 市場レポートで取り上げられている国は、ドイツ、フランス、イタリア、イギリス、スペイン、スイス、ロシア、オランダ、ベルギー、トルコ、その他のヨーロッパ諸国です。
ヨーロッパは、医薬品およびバイオテクノロジー分野の研究開発活動の増加に伴い、予測期間中に CAGR で成長すると予想されています。ドイツはヨーロッパ市場で市場を支配すると予想されています。ドイツは、主要な市場プレーヤーの存在とこの地域での技術進歩の増加により、主要国の 1 つです。
レポートの国別セクションでは、市場の現在および将来の傾向に影響を与える国内市場における個別の市場影響要因と規制の変更も提供しています。新規販売、交換販売、国の人口統計、規制行為、輸出入関税などのデータ ポイントは、各国の市場シナリオを予測するために使用される主要な指標の一部です。また、国別データの予測分析を提供する際には、ヨーロッパ ブランドの存在と可用性、および地元および国内ブランドとの競争が激しいか少ないために直面する課題、販売チャネルの影響も考慮されます。
新興経済におけるリンパ脈管筋腫症（LAM）の成長可能性と市場プレーヤーによる戦略的取り組みにより、ヨーロッパのリンパ脈管筋腫症（LAM）市場に新たな機会が生まれています。
ヨーロッパのリンパ脈管筋腫症 (LAM) 市場では、リンパ脈管筋腫症 (LAM) の販売に関する特定の業界における各国の成長、リンパ脈管筋腫症 (LAM) の進歩の影響、およびリンパ脈管筋腫症 (LAM) 市場へのサポートに関する規制シナリオの変化に関する詳細な市場分析も提供されます。データは、2019 年から 2028 年までの履歴期間について入手できます。
競争環境と欧州のリンパ脈管筋腫症（LAM）市場シェア分析
ヨーロッパのリンパ脈管筋腫症 (LAM) 市場の競争状況は、競合他社ごとに詳細を提供します。詳細には、会社概要、会社の財務状況、収益、市場の可能性、研究開発への投資、新しい市場への取り組み、生産拠点と施設、会社の強みと弱み、製品の発売、製品試験パイプライン、製品の承認、特許、製品の幅と幅、アプリケーションの優位性、技術ライフライン曲線が含まれます。提供されている上記のデータ ポイントは、リンパ脈管筋腫症 (LAM) 市場に関連する会社の焦点にのみ関連しています。
ヨーロッパでリンパ脈管筋腫症（LAM）治療薬を提供している主な企業は、ファイザー社、インタス・ファーマシューティカルズ社、アムニール・ファーマシューティカルズ社、ドクター・レディーズ・ラボラトリーズ社、ノバルティス社、ヒクマ・ファーマシューティカルズ社、トランスメディックス・グループ社、テルモ社、ハーシル社、ケア・ディクス社、XVIVO社、タージ・ファーマシューティカルズ社です。
市場プレーヤーによる戦略的取り組みと、リンパ脈管筋腫症 (LAM) に関する新たな技術的進歩により、慢性創傷治療のギャップが埋められています。
例えば、
- 2020年1月、アムニール・ファーマシューティカルズLLCは、同社の子会社であるインパックス・ラボラトリーズLLCが使用するエピネフリン自動注射器の使用を食品医薬品局FDAに警告した。警告には、このデバイスは患者に2倍の量を投与する可能性があると書かれていた。この概念は、結節性硬化症複合体LAMを患う患者の健康を害する可能性があり、エピネフリン自動注射器の生産を妨げる可能性がある。
市場プレーヤーによるコラボレーション、ジョイントベンチャー、およびその他の戦略により、ヨーロッパのリンパ脈管筋腫症 (LAM) 市場における企業市場が強化され、組織が治療製品の提供を改善するメリットももたらされます。
SKU-
世界初のマーケットインテリジェンスクラウドに関するレポートにオンラインでアクセスする
- インタラクティブなデータ分析ダッシュボード
- 成長の可能性が高い機会のための企業分析ダッシュボード
- カスタマイズとクエリのためのリサーチアナリストアクセス
- インタラクティブなダッシュボードによる競合分析
- 最新ニュース、更新情報、トレンド分析
- 包括的な競合追跡のためのベンチマーク分析のパワーを活用
目次
1 INTRODUCTION
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.3 OVERVIEW OF THE EUROPE LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET
1.4 CURRENCY AND PRICING
1.5 LIMITATIONS
1.6 MARKETS COVERED
2 EUROPE LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET: SEGMENTATION
2.1 MARKETS COVERED
2.2 GEOGRAPHICAL SCOPE
2.3 YEARS CONSIDERED FOR THE STUDY
2.4 DBMR TRIPOD DATA VALIDATION MODEL
2.5 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS
2.6 MULTIVARIATE MODELLING
2.7 DISEASE TYPE LIFELINE CURVE
2.8 DBMR MARKET POSITION GRID
2.9 VENDOR SHARE ANALYSIS
2.1 MARKET INDICATION COVERAGE GRID
2.11 SECONDARY SOURCES
2.12 ASSUMPTIONS
3 EXECUTIVE SUMMARY
4 PREMIUM INSIGHTS
5 PIPELINE ANALYSIS
6 EUROPE LYMPHANGIOLEIOMYOMATOSIS MARKET: REGULATIONS
7 MARKET OVERVIEW
7.1 DRIVERS
7.1.1 RISE IN PREVALENCE OF CHRONIC CYSTIC LUNG DISORDERS
7.1.2 RISE OF ANGIOMYOLIPOMA AND TUBEROUS SCLEROSIS COMPLEX (TSC) IN WOMEN
7.1.3 RISE IN GOVERNMENT INITIATIVES AND ORGANIZATIONS
7.1.4 RISE IN CLINICAL TRIALS
7.1.5 HEALTHCAREREIMBURSEMENTFOR LYMPHANGIOLEIOMYOMATOSIS
7.2 RESTRAINTS
7.2.1 RISE IN COST FOR LYMPHANGIOLEIOMYOMATOSIS (LAM) TREATMENT
7.2.2 AVAILABILITY OF ALTERNATIVES
7.2.3 HIGH COMPLEXITY IN LAM
7.2.4 STRICT REGULATORY FRAMEWORK
7.3 OPPORTUNITIES
7.3.1 RISE IN HEALTHCARE EXPENDITURE
7.3.2 RISE IN PRODUCT APPROVALS
7.3.3 USE OF NON-INVASIVE PROCEDURE
7.4 CHALLENGES
7.4.1 SIDE EFFECTS FOUND DURING LAM TREATMENT
7.4.2 PATIENT COMPLIANCE DURING THE TREATMENT OF LAM
8 IMPACT OF COVID-19 ON EUROPE LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET
8.1 ANALYSIS ON IMPACT OF COVID-19 ON LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET
8.2 IMPACT ON PRICE OF LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET
8.3 IMPACT ON DEMAND OF LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET
8.4 IMPACT ON SUPPLY CHAIN OF LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET
8.5 STRATEGIC DECISIONS BY MANUFACTURERS OF LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET
8.6 CONCLUSION
9 EUROPE LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY DISEASE TYPE
9.1 OVERVIEW
9.2 TUBEROUS SCLEROSIS COMPLEX LAM
9.3 SPORADIC LAM
10 EUROPE LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY TYPE
10.1 OVERVIEW
10.2 TREATMENT
10.2.1 MEDICATION
10.2.2 MTOR INHIBITORS
10.2.3 SIROLIMUS/ RAPAMYCIN
10.2.4 EVEROLIMUS
10.2.5 OTHERS
10.2.6 BRONCHODILATORS
10.2.7 ALBUTEROL
10.2.8 SALMETEROL
10.2.9 GLYCOPYRROLATE
10.2.10 OTHERS
10.2.11 OXYGEN THERAPY
10.2.12 LUNG TRANSPLANTATION
10.2.13 BILATERAL LUNG TRANSPLANTATION (BLT)
10.2.14 SINGLE-LUNG TRANSPLANTATION (SLT)
10.3 DIAGNOSIS
10.3.1 IMAGING TEST
10.3.2 CHEST X-RAYS
10.3.3 CHEST CT SCANS
10.3.4 MRI OF ABDOMEN
10.3.5 OTHERS
10.3.6 LUNG FUNCTION TEST
10.3.7 BLOOD TEST (VASCULAR ENDOTHELIAL GROWTH FACTOR D (VEGF-D))
10.3.8 LUNG BIOPSY
10.3.9 VIDEO-ASSISTED THORASCOPIC LUNG BIOPSY
10.3.10 TRANSBRONCHIAL LUNG BIOPSY
10.3.11 OTHERS
10.3.12 OTHERS
11 EUROPE LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY COMPLICATIONS
11.1 OVERVIEW
11.2 PNEUMOTHORAX
11.3 PLEURAL EFFUSIONS
11.4 KIDNEY TUMOR
11.5 CHYLOTHORAX
11.6 SWELLING & FLUID BUILD-UP
11.7 OTHERS
12 EUROPE LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY ROUTE OF ADMINISTRATION
12.1 OVERVIEW
12.2 ORAL
12.2.1 TABLET
12.2.2 CAPSULES
12.2.3 OTHERS
12.3 PARENTERAL
12.3.1 INTRAVENOUS
12.3.2 SUBCUTANEOUS
12.3.3 OTHERS
13 EUROPE LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY END USER
13.1 OVERVIEW
13.2 HOSPITALS
13.3 SPECIALTY CLINICS
13.4 DIAGNOSTIC CENTER
13.5 HOME HEALTHCARE
13.6 OTHERS
14 EUROPE LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY DISTRIBUTION CHANNEL
14.1 OVERVIEW
14.2 DIRECT TENDER
14.3 HOSPITAL PHARMACIES
14.4 RETAIL PHARMACIES
14.5 ONLINE PHARMACIES
14.6 OTHERS
15 EUROPE LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY REGION
15.1 OVERVIEW
15.2 EUROPE
15.2.1 GERMANY
15.2.2 FRANCE
15.2.3 U.K.
15.2.4 HUNGARY
15.2.5 LITHUANIA
15.2.6 AUSTRIA
15.2.7 IRELAND
15.2.8 NORWAY
15.2.9 POLAND
15.2.10 ITALY
15.2.11 SPAIN
15.2.12 RUSSIA
15.2.13 TURKEY
15.2.14 NETHERLANDS
15.2.15 SWITZERLAND
15.2.16 REST OF EUROPE
16 EUROPE LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET: COMPANY LANDSCAPE
16.1 COMPANY SHARE ANALYSIS: EUROPE
17 COMPANY PROFILE
17.1 TERUMO CORPORATION
17.1.1 COMPANY SNAPSHOT
17.1.2 REVENUE ANALYSIS
17.1.3 COMPANY SHARE ANALYSIS
17.1.4 PRODUCT PORTFOLIO
17.1.5 RECENT DEVELOPMENTS
17.2 CAREDX, INC.
17.2.1 COMPANY SNAPSHOT
17.2.2 REVENUE ANALYSIS
17.2.3 COMPANY SHARE ANALYSIS
17.2.4 PRODUCT PORTFOLIO
17.2.5 RECENT DEVELOPMENTS
17.3 PFIZER INC.
17.3.1 COMPANY SNAPSHOT
17.3.2 REVENUE ANALYSIS
17.3.3 COMPANY SHARE ANALYSIS
17.3.4 PRODUCT PORTFOLIO
17.3.5 RECENT DEVELOPMENTS
17.4 NOVARTIS AG
17.4.1 COMPANY SNAPSHOT
17.4.2 REVENUE ANALYSIS
17.4.3 COMPANY SHARE ANALYSIS
17.4.4 PRODUCT PORTFOLIO
17.4.5 RECENT DEVELOPMENTS
17.5 ZYDUS PHARMACEUTICALS, INC. (A SUBSIDIARY OF ZYDUS CADILA)
17.5.1 COMPANY SNAPSHOT
17.5.2 REVENUE ANALYSIS
17.5.3 PRODUCT PORTFOLIO
17.5.4 RECENT DEVELOPMENTS
17.6 APOTEX INC
17.6.1 COMPANY SNAPSHOT
17.6.2 PRODUCT PORTFOLIO
17.6.3 RECENT DEVELOPMENTS
17.7 AMNEAL PHARMACEUTICALS LLC
17.7.1 COMPANY SNAPSHOT
17.7.2 REVENUE ANALYSIS
17.7.3 PRODUCT PORTFOLIO
17.7.4 RECENT DEVELOPMENTS
17.8 HIKMA PHARMACEUTICALS PLC
17.8.1 COMPANY SNAPSHOT
17.8.2 REVENUE ANALYSIS
17.8.3 PRODUCT PORTFOLIO
17.8.4 RECENT DEVELOPMENTS
17.9 HERSILL
17.9.1 COMPANY SNAPSHOT
17.9.2 PRODUCT PORTFOLIO
17.9.3 RECENT DEVELOPMENTS
17.1 HOME OXYGEN COMPANY
17.10.1 COMPANY SNAPSHOT
17.10.2 PRODUCT PORTFOLIO
17.10.3 RECENT DEVELOPMENT
17.11 INTAS PHARMACEUTICALS, LTD
17.11.1 COMPANY SNAPSHOT
17.11.2 PRODUCT PORTFOLIO
17.11.3 RECENT DEVELOPMENT
17.12 INOGEN INC.
17.12.1 COMPANY SNAPSHOT
17.12.2 REVENUE ANALYSIS
17.12.3 PRODUCT PORTFOLIO
17.12.4 RECENT DEVELOPMENTS
17.13 MORGAN SCIENTIFIC
17.13.1 COMPANY SNAPSHOT
17.13.2 PRODUCT PORTFOLIO
17.13.3 RECENT DEVELOPMENTS
17.14 PULMONE ADVANCED MEDICAL DEVICES
17.14.1 COMPANY SNAPSHOT
17.14.2 PRODUCT PORTFOLIO
17.14.3 RECENT DEVELOPMENTS
17.15 PARAGONIX TECHNOLOGIES, INC
17.15.1 COMPANY SNAPSHOT
17.15.2 PRODUCT PORTFOLIO
17.15.3 RECENT DEVELOPMENTS
17.16 DR REDDY’S LABORATORIES LTD.
17.16.1 COMPANY SNAPSHOT
17.16.2 REVENUE ANALYSIS
17.16.3 PRODUCT PORTFOLIO
17.16.4 RECENT DEVELOPMENT
17.17 SANDOR
17.17.1 COMPANY SNAPSHOT
17.17.2 PRODUCT PORTFOLIO
17.17.3 RECENT DEVELOPMENT
17.18 TEVA PHARMACEUTICALS USA, INC. (A SUBSIDIARY OF TEVA PHARMACEUTICALS INDUSTRIES LTD)
17.18.1 COMPANY SNAPSHOT
17.18.2 REVENUE ANALYSIS
17.18.3 PRODUCT PORTFOLIO
17.18.4 RECENT DEVELOPMENTS
17.19 TRANSMEDICS GROUP INC
17.19.1 COMPANY SNAPSHOT
17.19.2 REVENUE ANALYSIS
17.19.3 PRODUCT PORTFOLIO
17.19.4 RECENT DEVELOPMENTS
17.2 TAJ PHARMACEUTICALS LTD
17.20.1 COMPANY SNAPSHOT
17.20.2 PRODUCT PORTFOLIO
17.20.3 RECENT DEVELOPMENT
17.21 XVIVO
17.21.1 COMPANY SNAPSHOT
17.21.2 REVENUE ANALYSIS
17.21.3 PRODUCT PORTFOLIO
17.21.4 RECENT DEVELOPMENTS
18 QUESTIONNAIRE
19 RELATED REPORTS
表のリスト
TABLE 1 EUROPE LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET: PIPELINE ANALYSIS
TABLE 2 EUROPE LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY DISEASE TYPE, 2019-2028 (USD MILLION)
TABLE 3 EUROPE TUBEROUS SCLEROSIS COMPLEX LAM IN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 4 EUROPE SPORADIC LAM IN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 5 EUROPE LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 6 EUROPE TREATMENT IN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 7 EUROPE TREATMENT IN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 8 EUROPE MEDICATION IN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 9 EUROPE MTOR INHIBITORS IN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 10 EUROPE BRONCHODILATORS IN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 11 EUROPE LUNG TRANSPLANTATION IN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 12 EUROPE DIAGNOSIS IN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 13 EUROPE DIAGNOSIS IN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 14 EUROPE IMAGING TEST IN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 15 EUROPE LUNG BIOPSY IN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 16 EUROPE LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY COMPLICATIONS, 2019-2028 (USD MILLION)
TABLE 17 EUROPE PNEUMOTHORAX IN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 18 EUROPE PLEURAL EFFUSIONS IN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 19 EUROPE KIDNEY TUMOR IN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 20 EUROPE CHYLOTHORAX IN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 21 EUROPE SWELLING & FLUID BUILD-UP IN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 22 EUROPE OTHERS IN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 23 EUROPE LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 24 EUROPE ORAL IN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 25 EUROPE ORAL IN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY ROUTE OF ADMINISTRATION , 2019-2028 (USD MILLION)
TABLE 26 EUROPE PARENTERAL IN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 27 EUROPE PARENTERAL IN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 28 EUROPE LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 29 EUROPE HOSPITALS IN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 30 EUROPE SPECIALTY CLINICS IN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 31 EUROPE DIAGNOSTIC CENTER IN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 32 EUROPE HOME HEALTHCARE IN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 33 EUROPE OTHERS IN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 34 EUROPE LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY DISTRIBUTION CHANNEL 2019-2028 (USD MILLION)
TABLE 35 EUROPE DIRECT TENDER IN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 36 EUROPE HOSPITAL PHARMACIES IN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 37 EUROPE RETAIL PHARMACIES IN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 38 EUROPE ONLINE PHARMACIES IN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 39 EUROPE OTHERS IN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 40 EUROPE LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 41 EUROPE LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY COUNTRY, 2019-2028 (USD MILLION)
TABLE 42 EUROPE LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY DISEASE TYPE, 2019-2028 (USD MILLION)
TABLE 43 EUROPE LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 44 EUROPE TREATMENT IN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 45 EUROPE MEDICATION IN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 46 EUROPE MTOR INHIBITORS IN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 47 EUROPE BRONCHODILATORS IN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 48 EUROPE LUNG TRANSPLANTATION IN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 49 EUROPE DIAGNOSIS IN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 50 EUROPE IMAGING TEST IN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 51 EUROPE LUNG BIOPSY IN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 52 EUROPE LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY COMPLICATIONS, 2019-2028 (USD MILLION)
TABLE 53 EUROPE LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 54 EUROPE ORAL IN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 55 EUROPE PARENTERAL IN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 56 EUROPE LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 57 EUROPE LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
TABLE 58 GERMANY LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY DISEASE TYPE, 2019-2028 (USD MILLION)
TABLE 59 GERMANY LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 60 GERMANY TREATMENT IN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 61 GERMANY MEDICATION IN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 62 GERMANY MTOR INHIBITORS IN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 63 GERMANY BRONCHODILATORS IN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 64 GERMANY LUNG TRANSPLANTATION IN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 65 GERMANY DIAGNOSIS IN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 66 GERMANY IMAGING TEST IN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 67 GERMANY LUNG BIOPSY IN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 68 GERMANY LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY COMPLICATIONS, 2019-2028 (USD MILLION)
TABLE 69 GERMANY LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 70 GERMANY ORAL IN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 71 GERMANY PARENTERAL IN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 72 GERMANY LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 73 GERMANY LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
TABLE 74 FRANCE LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY DISEASE TYPE, 2019-2028 (USD MILLION)
TABLE 75 FRANCE LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 76 FRANCE TREATMENT IN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 77 FRANCE MEDICATION IN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 78 FRANCE MTOR INHIBITORS IN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 79 FRANCE BRONCHODILATORS IN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 80 FRANCE LUNG TRANSPLANTATION IN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 81 FRANCE DIAGNOSIS IN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 82 FRANCE IMAGING TEST IN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 83 FRANCE LUNG BIOPSY IN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 84 FRANCE LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY COMPLICATIONS, 2019-2028 (USD MILLION)
TABLE 85 FRANCE LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 86 FRANCE ORAL IN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 87 FRANCE PARENTERAL IN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 88 FRANCE LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 89 FRANCE LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
TABLE 90 U.K. LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY DISEASE TYPE, 2019-2028 (USD MILLION)
TABLE 91 U.K. LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 92 U.K. TREATMENT IN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 93 U.K. MEDICATION IN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 94 U.K. MTOR INHIBITORS IN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 95 U.K. BRONCHODILATORS IN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 96 U.K. LUNG TRANSPLANTATION IN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 97 U.K. DIAGNOSIS IN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 98 U.K. IMAGING TEST IN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 99 U.K. LUNG BIOPSY IN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 100 U.K. LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY COMPLICATIONS, 2019-2028 (USD MILLION)
TABLE 101 U.K. LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 102 U.K. ORAL IN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 103 U.K. PARENTERAL IN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 104 U.K. LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 105 U.K. LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
TABLE 106 HUNGARY LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY DISEASE TYPE, 2019-2028 (USD MILLION)
TABLE 107 HUNGARY LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 108 HUNGARY TREATMENT IN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 109 HUNGARY MEDICATION IN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 110 HUNGARY MTOR INHIBITORS IN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 111 HUNGARY BRONCHODILATORS IN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 112 HUNGARY LUNG TRANSPLANTATION IN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 113 HUNGARY DIAGNOSIS IN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 114 HUNGARY IMAGING TEST IN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 115 HUNGARY LUNG BIOPSY IN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 116 HUNGARY LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY COMPLICATIONS, 2019-2028 (USD MILLION)
TABLE 117 HUNGARY LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 118 HUNGARY ORAL IN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 119 HUNGARY PARENTERAL IN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 120 HUNGARY LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 121 HUNGARY LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
TABLE 122 LITHUANIA LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY DISEASE TYPE, 2019-2028 (USD MILLION)
TABLE 123 LITHUANIA LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 124 LITHUANIA TREATMENT IN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 125 LITHUANIA MEDICATION IN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 126 LITHUANIA MTOR INHIBITORS IN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 127 LITHUANIA BRONCHODILATORS IN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 128 LITHUANIA LUNG TRANSPLANTATION IN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 129 LITHUANIA DIAGNOSIS IN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 130 LITHUANIA IMAGING TEST IN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 131 LITHUANIA LUNG BIOPSY IN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 132 LITHUANIA LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY COMPLICATIONS, 2019-2028 (USD MILLION)
TABLE 133 LITHUANIA LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 134 LITHUANIA ORAL IN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 135 LITHUANIA PARENTERAL IN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 136 LITHUANIA LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 137 LITHUANIA LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
TABLE 138 AUSTRIA LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY DISEASE TYPE, 2019-2028 (USD MILLION)
TABLE 139 AUSTRIA LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 140 AUSTRIA TREATMENT IN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 141 AUSTRIA MEDICATION IN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 142 AUSTRIA MTOR INHIBITORS IN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 143 AUSTRIA BRONCHODILATORS IN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 144 AUSTRIA LUNG TRANSPLANTATION IN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 145 AUSTRIA DIAGNOSIS IN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 146 AUSTRIA IMAGING TEST IN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 147 AUSTRIA LUNG BIOPSY IN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 148 AUSTRIA LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY COMPLICATIONS, 2019-2028 (USD MILLION)
TABLE 149 AUSTRIA LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 150 AUSTRIA ORAL IN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 151 AUSTRIA PARENTERAL IN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 152 AUSTRIA LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 153 AUSTRIA LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
TABLE 154 IRELAND LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY DISEASE TYPE, 2019-2028 (USD MILLION)
TABLE 155 IRELAND LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 156 IRELAND TREATMENT IN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 157 IRELAND MEDICATION IN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 158 IRELAND MTOR INHIBITORS IN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 159 IRELAND BRONCHODILATORS IN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 160 IRELAND LUNG TRANSPLANTATION IN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 161 IRELAND DIAGNOSIS IN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 162 IRELAND IMAGING TEST IN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 163 IRELAND LUNG BIOPSY IN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 164 IRELAND LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY COMPLICATIONS, 2019-2028 (USD MILLION)
TABLE 165 IRELAND LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 166 IRELAND ORAL IN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 167 IRELAND PARENTERAL IN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 168 IRELAND LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 169 IRELAND LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
TABLE 170 NORWAY LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY DISEASE TYPE, 2019-2028 (USD MILLION)
TABLE 171 NORWAY LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 172 NORWAY TREATMENT IN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 173 NORWAY MEDICATION IN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 174 NORWAY MTOR INHIBITORS IN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 175 NORWAY BRONCHODILATORS IN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 176 NORWAY LUNG TRANSPLANTATION IN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 177 NORWAY DIAGNOSIS IN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 178 NORWAY IMAGING TEST IN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 179 NORWAY LUNG BIOPSY IN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 180 NORWAY LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY COMPLICATIONS, 2019-2028 (USD MILLION)
TABLE 181 NORWAY LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 182 NORWAY ORAL IN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 183 NORWAY PARENTERAL IN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 184 NORWAY LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 185 NORWAY LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
TABLE 186 POLAND LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY DISEASE TYPE, 2019-2028 (USD MILLION)
TABLE 187 POLAND LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 188 POLAND TREATMENT IN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 189 POLAND MEDICATION IN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 190 POLAND MTOR INHIBITORS IN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 191 POLAND BRONCHODILATORS IN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 192 POLAND LUNG TRANSPLANTATION IN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 193 POLAND DIAGNOSIS IN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 194 POLAND IMAGING TEST IN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 195 POLAND LUNG BIOPSY IN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 196 POLAND LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY COMPLICATIONS, 2019-2028 (USD MILLION)
TABLE 197 POLAND LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 198 POLAND ORAL IN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 199 POLAND PARENTERAL IN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 200 POLAND LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 201 POLAND LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
TABLE 202 ITALY LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY DISEASE TYPE, 2019-2028 (USD MILLION)
TABLE 203 ITALY LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 204 ITALY TREATMENT IN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 205 ITALY MEDICATION IN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 206 ITALY MTOR INHIBITORS IN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 207 ITALY BRONCHODILATORS IN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 208 ITALY LUNG TRANSPLANTATION IN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 209 ITALY DIAGNOSIS IN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 210 ITALY IMAGING TEST IN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 211 ITALY LUNG BIOPSY IN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 212 ITALY LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY COMPLICATIONS, 2019-2028 (USD MILLION)
TABLE 213 ITALY LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 214 ITALY ORAL IN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 215 ITALY PARENTERAL IN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 216 ITALY LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 217 ITALY LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
TABLE 218 SPAIN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY DISEASE TYPE, 2019-2028 (USD MILLION)
TABLE 219 SPAIN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 220 SPAIN TREATMENT IN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 221 SPAIN MEDICATION IN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 222 SPAIN MTOR INHIBITORS IN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 223 SPAIN BRONCHODILATORS IN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 224 SPAIN LUNG TRANSPLANTATION IN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 225 SPAIN DIAGNOSIS IN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 226 SPAIN IMAGING TEST IN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 227 SPAIN LUNG BIOPSY IN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 228 SPAIN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY COMPLICATIONS, 2019-2028 (USD MILLION)
TABLE 229 SPAIN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 230 SPAIN ORAL IN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 231 SPAIN PARENTERAL IN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 232 SPAIN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 233 SPAIN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
TABLE 234 RUSSIA LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY DISEASE TYPE, 2019-2028 (USD MILLION)
TABLE 235 RUSSIA LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 236 RUSSIA TREATMENT IN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 237 RUSSIA MEDICATION IN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 238 RUSSIA MTOR INHIBITORS IN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 239 RUSSIA BRONCHODILATORS IN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 240 RUSSIA LUNG TRANSPLANTATION IN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 241 RUSSIA DIAGNOSIS IN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 242 RUSSIA IMAGING TEST IN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 243 RUSSIA LUNG BIOPSY IN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 244 RUSSIA LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY COMPLICATIONS, 2019-2028 (USD MILLION)
TABLE 245 RUSSIA LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 246 RUSSIA ORAL IN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 247 RUSSIA PARENTERAL IN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 248 RUSSIA LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 249 RUSSIA LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
TABLE 250 TURKEY LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY DISEASE TYPE, 2019-2028 (USD MILLION)
TABLE 251 TURKEY LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 252 TURKEY TREATMENT IN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 253 TURKEY MEDICATION IN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 254 TURKEY MTOR INHIBITORS IN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 255 TURKEY BRONCHODILATORS IN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 256 TURKEY LUNG TRANSPLANTATION IN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 257 TURKEY DIAGNOSIS IN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 258 TURKEY IMAGING TEST IN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 259 TURKEY LUNG BIOPSY IN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 260 TURKEY LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY COMPLICATIONS, 2019-2028 (USD MILLION)
TABLE 261 TURKEY LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 262 TURKEY ORAL IN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 263 TURKEY PARENTERAL IN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 264 TURKEY LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 265 TURKEY LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
TABLE 266 NETHERLAND LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY DISEASE TYPE, 2019-2028 (USD MILLION)
TABLE 267 NETHERLAND LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 268 NETHERLAND TREATMENT IN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 269 NETHERLAND MEDICATION IN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 270 NETHERLAND MTOR INHIBITORS IN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 271 NETHERLAND BRONCHODILATORS IN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 272 NETHERLAND LUNG TRANSPLANTATION IN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 273 NETHERLAND DIAGNOSIS IN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 274 NETHERLAND IMAGING TEST IN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 275 NETHERLAND LUNG BIOPSY IN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 276 NETHERLAND LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY COMPLICATIONS, 2019-2028 (USD MILLION)
TABLE 277 NETHERLAND LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 278 NETHERLAND ORAL IN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 279 NETHERLAND PARENTERAL IN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 280 NETHERLAND LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 281 NETHERLAND LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
TABLE 282 SWITZERLAND LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY DISEASE TYPE, 2019-2028 (USD MILLION)
TABLE 283 SWITZERLAND LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 284 SWITZERLAND TREATMENT IN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 285 SWITZERLAND MEDICATION IN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 286 SWITZERLAND MTOR INHIBITORS IN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 287 SWITZERLAND BRONCHODILATORS IN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 288 SWITZERLAND LUNG TRANSPLANTATION IN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 289 SWITZERLAND DIAGNOSIS IN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 290 SWITZERLAND IMAGING TEST IN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 291 SWITZERLAND LUNG BIOPSY IN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 292 SWITZERLAND LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY COMPLICATIONS, 2019-2028 (USD MILLION)
TABLE 293 SWITZERLAND LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 294 SWITZERLAND ORAL IN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 295 SWITZERLAND PARENTERAL IN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 296 SWITZERLAND LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 297 SWITZERLAND LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
TABLE 298 REST OF EUROPE LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY DISEASE TYPE, 2019-2028 (USD MILLION)
図表一覧
FIGURE 1 EUROPE LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET: SEGMENTATION
FIGURE 2 EUROPE LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET: DATA TRIANGULATION
FIGURE 3 EUROPE LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET: DROC ANALYSIS
FIGURE 4 EUROPE LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET: EUROPE VS REGIONAL ANALYSIS
FIGURE 5 EUROPE LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET: COMPANY RESEARCH ANALYSIS
FIGURE 6 EUROPE LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET: INTERVIEW DEMOGRAPHICS
FIGURE 7 EUROPE LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET: DBMR MARKET POSITION GRID
FIGURE 8 EUROPE LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET: VENDOR SHARE ANALYSIS
FIGURE 9 EUROPE LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET: MARKET INDICATION COVERAGE GRID
FIGURE 10 EUROPE LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET: SEGMENTATION
FIGURE 11 RISING PREVALENCE OF CHRONIC CYSTIC LUNG DISORDER , RISE IN CLINICAL TRIALS AND PRESENCE OF HEALTHCARE REIMBURSEMENT IS EXPECTED TO DRIVE THE EUROPE LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKETIN THE FORECAST PERIOD OF 2021 TO 2028
FIGURE 12 DISEASE TYPE SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE EUROPE LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET IN 2021 & 2028
FIGURE 13 NORTH AMERICA IS EXPECTED TO DOMINATE THE EUROPE LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET AND IS ALSO EXPECTED TO GROW WITH THE HIGHEST CAGR IN THE FORECAST PERIOD OF 2021 TO 2028
FIGURE 14 DRIVERS, RESTRAINTS, OPPORTUNITIES AND CHALLENGES OF EUROPE LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET
FIGURE 15 PREVALENCE OF CHRONIC PULMONARY (LUNG) CYSTS, WHICH INCREASES WITH AGE
FIGURE 16 PREVALENCE OF CHRONIC OBSTRUCTIVE PULMONARY DISORDER , HIGHER IN FEMALES
FIGURE 17 EUROPE LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET: BY DISEASE TYPE, 2020
FIGURE 18 EUROPE LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET: BY TYPE, 2020
FIGURE 19 EUROPE LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET: BY COMPLICATIONS, 2020
FIGURE 20 EUROPE LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET: BY ROUTE OF ADMINISTRATION, 2020
FIGURE 21 EUROPE LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET: BY END USER, 2020
FIGURE 22 EUROPE LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET: BY DISTRIBUTION CHANNEL, 2020
FIGURE 23 EUROPE LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET: SNAPSHOT (2020)
FIGURE 24 EUROPE LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET: BY REGION (2020)
FIGURE 25 EUROPE LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET: BY REGION (2021 & 2028)
FIGURE 26 EUROPE LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET: BY REGION (2020 & 2028)
FIGURE 27 EUROPE LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET: BY DISEASE TYPE (2021-2028)
FIGURE 28 EUROPE LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET: SNAPSHOT (2020)
FIGURE 29 EUROPE LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET: BY COUNTRY (2020)
FIGURE 30 EUROPE LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET: BY COUNTRY (2021 & 2028)
FIGURE 31 EUROPE LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET: BY COUNTRY (2020 & 2028)
FIGURE 32 EUROPE LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET: BY DISEASE TYPE (2021-2028)
FIGURE 33 EUROPE LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET: COMPANY SHARE 2020 (%)
調査方法
データ収集と基準年分析は、大規模なサンプル サイズのデータ収集モジュールを使用して行われます。この段階では、さまざまなソースと戦略を通じて市場情報または関連データを取得します。過去に取得したすべてのデータを事前に調査および計画することも含まれます。また、さまざまな情報ソース間で見られる情報の不一致の調査も含まれます。市場データは、市場統計モデルと一貫性モデルを使用して分析および推定されます。また、市場シェア分析と主要トレンド分析は、市場レポートの主要な成功要因です。詳細については、アナリストへの電話をリクエストするか、お問い合わせをドロップダウンしてください。
DBMR 調査チームが使用する主要な調査方法は、データ マイニング、データ変数が市場に与える影響の分析、および一次 (業界の専門家) 検証を含むデータ三角測量です。データ モデルには、ベンダー ポジショニング グリッド、市場タイムライン分析、市場概要とガイド、企業ポジショニング グリッド、特許分析、価格分析、企業市場シェア分析、測定基準、グローバルと地域、ベンダー シェア分析が含まれます。調査方法について詳しくは、お問い合わせフォームから当社の業界専門家にご相談ください。
カスタマイズ可能
Data Bridge Market Research は、高度な形成的調査のリーダーです。当社は、既存および新規のお客様に、お客様の目標に合致し、それに適したデータと分析を提供することに誇りを持っています。レポートは、対象ブランドの価格動向分析、追加国の市場理解 (国のリストをお問い合わせください)、臨床試験結果データ、文献レビュー、リファービッシュ市場および製品ベース分析を含めるようにカスタマイズできます。対象競合他社の市場分析は、技術ベースの分析から市場ポートフォリオ戦略まで分析できます。必要な競合他社のデータを、必要な形式とデータ スタイルでいくつでも追加できます。当社のアナリスト チームは、粗い生の Excel ファイル ピボット テーブル (ファクト ブック) でデータを提供したり、レポートで利用可能なデータ セットからプレゼンテーションを作成するお手伝いをしたりすることもできます。
